Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.43 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.43 |
| ▸ | NAAA | Q02083 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5536480 | 0.95 | HRH1 (0.53) | HRH1CYP1A2SMN1; SMN2CYP2C19CYP3A4 | |
| SCHEMBL5544618 | 0.93 | HRH1 (0.56) | HRH1CYP1A2SMN1; SMN2CYP2C19CYP3A4 | |
| SCHEMBL5252530 | 0.93 | HRH1 (0.56) | HRH1CYP1A2SMN1; SMN2CYP2C19CYP3A4 | |
| SCHEMBL5252807 | 0.89 | HRH1 (0.50) | HRH1CYP1A2SMN1; SMN2CYP2C19CYP3A4 | |
| Bromide SCHEMBL28768599 | 0.88 | CA12 (0.49) | HRH1CYP1A2SMN1; SMN2CYP2C19CYP3A4 | |
| Hydrochloric Acid SCHEMBL27562976 | 0.88 | CA12 (0.49) | HRH1CYP1A2SMN1; SMN2CYP2C19CYP3A4 | |
| Oxalic Acid SCHEMBL28208908 | 0.82 | CYP1A2 (0.48) | HRH1CYP1A2SMN1; SMN2CYP2C19CYP3A4 | |
| SCHEMBL7445422 | 0.80 | HRH1 (0.58) | HRH1CYP1A2SMN1; SMN2CYP2C19CYP3A4 | |
| SCHEMBL12299309 | 0.79 | SMN1; SMN2 (0.52) | SMN1; SMN2ALDH1A1TAAR1ALOX15 | |
| SCHEMBL1362405 | 0.78 | SMN1; SMN2 (0.57) | HRH1SMN1; SMN2ALDH1A1KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2004101582-A2 | THERMOLABILE HYDROXYL PROTECTING GROUPS AND METHODS OF USE | GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2004-11-25 | — | — | WO | claimed |
| CN-1187188-A | Small molecule inhibitors of rotamase enzyme activity | GUILFORD PHARM INC (US) | 1998-07-08 | — | — | CN | claimed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-7612197-B2 | Reacting a nucleophil with OH group with an electrophil to form an adduct, reacting adduct with a reagent selected from oxidizing, sulfurizing or selenizing agents to produce hydroxy protected oligonucleotide, heating to deprotect hydroxy protecting group such as 2-(2-pyridyl)aminoethoxycarbonyl | The United States of America as repesented by the Secretary of the Department of Health and Human Services (US) | 2009-11-03 | — | — | US | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| CN-1331853-C | Small molecule inhibitors of rotamase enzyme activity | GPI NIL HOLDINGS (US) | 2007-08-15 | — | — | CN | disclosed |
| US-20060281911-A1 | Thermolabile hydroxyl protecting groups and methods of use | GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH (US) | 2006-12-14 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| CN-1178912-C | Small molecule inhibitors of rotamase enzyme activity | ������˹ҩƷ��˾ | 2004-12-08 | — | — | CN | disclosed |
| WO-2004101582-A2 | THERMOLABILE HYDROXYL PROTECTING GROUPS AND METHODS OF USE | GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2004-11-25 | — | — | WO | disclosed |
| CN-1542001-A | Small molecule inhibitors of rotamase enzyme activity | GPI����عɹ�˾ | 2004-11-03 | — | — | CN | disclosed |
| CN-1336930-A | Bridged heterocyclic derivatives | GPINIL HOLDING CORP (US) | 2002-02-20 | — | — | CN | disclosed |
| CN-1187188-A | Small molecule inhibitors of rotamase enzyme activity | GUILFORD PHARM INC (US) | 1998-07-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | HRH1 668/4885CYP1A2 659/4885SMN1; SMN2 3985/4885 |
| US-20060281911-A1 | Thermolabile hydroxyl protecting groups and methods of use | ADH1A, CYP2E1, ADH1C | HRH1 431/4885CYP1A2 17/4885SMN1; SMN2 4626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.